Huntington disease (HD) is an autosomal dominant neurodegenerative disease with complete penetrance. Although the understanding of the cellular mechanisms that drive neurodegeneration in HD and account for the characteristic pattern of neuronal vulnerability is incomplete, defects in energy metabolism, particularly mitochondrial function, represent a common thread in studies of HD pathogenesis in humans and animal models. Here we review the clinical, biochemical, and molecular evidence of an energy deficit in HD and discuss the mechanisms underlying mitochondrial and related alterations.
Fanny Mochel, Ronald G. Haller
Title and authors | Publication | Year |
---|---|---|
IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington’s disease
Marianna Sadagurski, Zhiyong Cheng, Aldo Rozzo, Isabella Palazzolo, Gregory Kelley, Xiaocheng Dong, Dmitri Krainc, Morris White |
Journal of Clinical Investigation | 2011 |
The importance of integrating basic and clinical research towards the development of new therapies for Huntington’s disease
Ignacio Munoz-Sanjuan, gillain bates |
Journal of Clinical Investigation | 2011 |
Huntington’s Disease and Striatal Signaling
E Roze, E Cahill, E Martin, C Bonnet, P Vanhoutte, S Betuing, J Caboche |
Frontiers in neuroanatomy | 2011 |
Early alterations of brain cellular energy homeostasis in Huntington disease models
F Mochel, B Durant, X Meng, J O'Callaghan, H Yu, E Brouillet, VC Wheeler, S Humbert, R Schiffmann, A Durr |
The Journal of biological chemistry | 2011 |
Should metabolic diseases be systematically screened in nonsyndromic autism spectrum disorders?
M Schiff, JF Benoist, S Aïssaoui, O Boespflug-Tanguy, O Boepsflug-Tanguy, MC Mouren, HO de Baulny, R Delorme |
PloS one | 2011 |